Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus.

ABSTRACT: Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, but an effective vaccine has not yet been developed. An ideal vaccine would elicit protective antibodies while avoiding virus-specific T-cell responses, which have been implicated in vaccine-enhanced disease with previous RSV vaccines. We propose that heterologous proteins designed to present RSV-neutralizing antibody epitopes and to elicit cognate antibodies have the potential to fulfill these vaccine requirements, as they can be fashioned to be free of viral T-cell epitopes. Here we present the design and characterization of three epitope-scaffolds that present the epitope of motavizumab, a potent neutralizing antibody that binds to a helix-loop-helix motif in the RSV fusion glycoprotein. Two o

SUBMITTER: McLellan JS 

PROVIDER: S-EPMC3107930 | biostudies-literature | 2011 Jun

REPOSITORIES: biostudies-literature